Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
C-Tb + Tuberculin PPD RT 23 SSI
- Development stage
- Unknown
- Lead developer
- Statens Serum Institut
- Administration
- Intradermal
01
Overview
C-Tb + Tuberculin PPD RT 23 SSI appears to be a combination of two diagnostic agents used for tuberculosis (TB) testing. Tuberculin PPD RT 23 SSI is a purified protein derivative prepared from a culture of seven selected strains of Mycobacterium tuberculosis. It is used in the Mantoux test to help diagnose tuberculosis infection. One dose (0.1 mL) contains 2 Tuberculin Units, equal to 0.04 μg of Tuberculin PPD RT 23. C-Tb is likely a newer diagnostic agent being compared to Tuberculin PPD RT 23 SSI in clinical trials for TB diagnosis.
02
Targets
ESAT-6/CFP-10-specific T-cell receptorT-cell receptor-peptide-MHC II complex (TCR-pMHC II)
Beyond the preview
Go deeper on C-Tb + Tuberculin PPD RT 23 SSI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on C-Tb + Tuberculin PPD RT 23 SSI.